CSIMarket


Atai Life Sciences N v   (ATAI)
Other Ticker:  
 


 

Atai Life Sciences N v

ATAI's Financial Statements and Analysis



Atai Life Sciences N v reported in the third quarter of 2023 net earnings per share of $0.25 an improvement compare to net loss per share of $-0.22 recorded a year ago and an improvement compare to net loss per share of $-0.21 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ 0.25 $  0 Mill
$+0.47     Unch.     +262.5 %



Atai Life Sciences N V 's Revenue rose by 262.5 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by -49.42 % sequentially.


Atai Life Sciences N V is

More on ATAI's Income Statement



Atai Life Sciences N V 's net income of $43.371 million in the third quarter of 2023 increased from net loss of $-35.701 million III. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-33.771 million recorded in previous quarter.

More on ATAI's Growth

Atai Life Sciences N V Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-65 million, capital expenditures grew by -0.529-99.62%, to $0 millions compare to same quarter a year ago

More on ATAI's Cash flow Statement


Atai Life Sciences N v does not pay out common stock dividend.

In trailing twelve-month period Atai Life Sciences N v payed $ -0.52 cash per share, on a free-cash flow basis .

Book value grew by 9.25 % sequentially to $1.51 per share.
Tangible Book value grew to $ 1.51 per share from $ 1.38.

Company issued 21.77 million shares or 13.98 % in Sep 30 2023.


More on ATAI's Dividends

 Market Capitalization (Millions) 295
 Shares Outstanding (Millions) 178
 Total Debt (Millions $) 15
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -66
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Atai Life Sciences N v does not pay out common stock dividend.

In trailing twelve-month period Atai Life Sciences N v had negative $ -0.52 cash flow per share, on a free-cash flow basis .

Book value grew by 9.25 % sequentially to $1.51 per share.
Tangible Book value grew to $ 1.51 per share from $ 1.38.

Company issued 21.77 million shares or 13.98 % in Sep 30 2023.


More on ATAI's Balance Sheets

 Market Capitalization (Millions) 295
 Shares Outstanding (Millions) 178
 Total Debt (Millions $) 15
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -66
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Atai Life Sciences N v Earnings

Leading Pharmaceutical Company Soars: Revenues Skyrocket while EPS Shows Remarkable Improvement in Q3 2023



ATAI Life Sciences N.V., a major pharmaceutical preparations company, has recently released its financial results for the July to September 30, 2023 period. The company showcased an impressive revenue rise of 262.5% year on year to $0.09 million. More notably, ATAIs achieved a surplus and presented earnings per share (EPS) at $0.25, marking a significant improvement compared to the preceding quarter. This article will delve into the facts and interpret the financial results while pondering the potential implications for the company's future.
Revenue Surge and EPS Advancement:
ATAI Life Sciences recorded remarkable revenue growth, with a surge of 262.5% year on year. This robust performance ...

Atai Life Sciences N.V. Defies Industry Trend with Revenue Surge in Q2 2023 Earnings Season

Atai Life Sciences N.V. Reports Soft Revenue Growth in Q2 2023 Earnings Season
During the second quarter of the 2023 earnings season, Atai Life Sciences N.V. faced a net loss of $-0.21 per share. This was an improvement from the previous year's figure of $-0.24 per share. Comparatively, the company had reported a net loss of $-0.21 per share in the previous reporting season. The Revenue for the quarter showed a slight increase of 1.176% to $0.17 million, remaining consistent with the same reporting period the previous year. However, the sequential Revenue surged significantly by 364.865% from $0.04 million.
Atai Life Sciences N.V., a major player in the Major Pharmaceutical Preparations industry, def...

1. Revised headline: Atai Life Sciences N V Reports Positive Revenue of $0.037 Million in First Quarter 20232. Subtitle: Advancing Psychedelic Drug Development for Mental Health Treatment: Atai Life Sciences N V Shows Promising Financial Progress

Atai Life Sciences N V, the biopharmaceutical company focused on developing psychedelic drugs for mental health treatment, has announced its financial results for the first quarter of the 2023 earnings season. The company reported $0.037 million in revenue, which is a positive sign for investors after the company's struggles in the past.
However, the company also reported a net shortfall of $-34.354 million in the first quarter, which is better than the deficit of $-37.558 million in the same period a year ago. This improvement in their financial performance is a welcome development for Atai Life Sciences N V investors.
Atai Life Sciences N V's management team has been working hard to develop and ad...


Date modified: 2023-11-16T18:28:42+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com